--- name: managing-iv-therapy language: en description: Guides IV access assessment, site management, and complication monitoring with documentation. Use when managing IV therapy, assessing IV sites, or documenting infusion monitoring. tags: - management - nursing metadata: author: casemark practice_areas: - Nursing - Advanced Practice - Nurse Practitioner document_types: - Management Report skill_modes: - Management - Coordination --- # Managing IV Therapy ## Why This Skill Exists Intravenous therapy is among the most common invasive procedures in healthcare, with over 90% of hospitalized patients receiving some form of IV therapy. The Infusion Nurses Society (INS) Standards of Practice (2021 edition) provide the evidence-based framework for vascular access device (VAD) selection, insertion, maintenance, and complication management. Infiltration and phlebitis are the most common IV complications, while catheter-related bloodstream infections (CRBSI) carry mortality rates of 12–25%. Joint Commission NPSG.07.04.01 (now consolidated under NPSG.07.06.01 for CLABSI) requires evidence-based practices for central line management. CMS considers CLABSI a Hospital-Acquired Condition with reimbursement implications. This skill ensures that nursing management of IV therapy follows INS standards for site assessment, maintenance, complication recognition, and documentation. --- ## Checkpoint A — Intake Verification ### Required Patient Information - [ ] Indication for IV therapy (hydration, medication administration, TPN, blood products, hemodynamic monitoring) - [ ] Vascular access history: number of prior attempts, known difficult access, history of DVT or lymphedema affecting access - [ ] Current vascular access inventory: type, location, gauge, insertion date for each device - [ ] Allergy status: latex, chlorhexidine, adhesive tape, iodine - [ ] Anticoagulant status affecting insertion/removal decisions - [ ] Current infusion orders: fluid type, rate, medications, additives, compatibility requirements ### Required References - [ ] INS Standards of Practice (current edition) - [ ] Institutional IV therapy policy and procedure manual - [ ] IV medication compatibility reference (Trissel's or institutional equivalent) - [ ] Smart pump drug library with facility-specific entries --- ## Step 1 — Select Appropriate Vascular Access Device Match device to therapy per INS recommendations: 1. **Short peripheral IV catheter (PIV)**: - Duration: < 6 days for most indications - Gauge selection: 22–24G for routine hydration/medication; 20G for blood transfusion, CT contrast; 18G for rapid fluid resuscitation, surgical cases - Preferred sites: forearm (most stable), hand; avoid antecubital fossa for non-emergent access (limits mobility, higher infiltration risk) 2. **Midline catheter**: - Duration: 1–4 weeks - Inserted in upper arm; tip terminates below the axilla, above the antecubital fossa - Suitable for: non-vesicant, non-irritant medications with pH 5–9 and osmolality < 900 mOsm/L 3. **Peripherally Inserted Central Catheter (PICC)**: - Duration: weeks to months - Tip terminates at the cavoatrial junction (confirmed by chest x-ray or intracavitary ECG) - Suitable for: vesicants, irritants, TPN, vasoactive medications, prolonged IV antibiotics 4. **Central Venous Catheter (CVC)**: - Non-tunneled: short-term ICU use (days to weeks) - Tunneled (Hickman, Broviac): long-term use (weeks to months) - Implanted port: intermittent long-term access (months to years) 5. **Intraosseous (IO)**: Emergency vascular access when IV access cannot be established within the clinical timeframe --- ## Step 2 — Assess IV Site Per INS Standards Perform and document IV site assessment at the following intervals: - **PIV**: At minimum every 4 hours for adults; every 1–2 hours for pediatrics, neonates, and critically ill; and with each medication administration - **PICC/CVC**: Each shift and with each access/use ### Assessment Parameters 1. **Insertion site inspection**: redness, swelling, drainage, tenderness, warmth 2. **Dressing integrity**: clean, dry, intact, occlusive; transparent dressing allows continuous visualization 3. **Securement**: catheter stabilization device in place; no tension on tubing 4. **Phlebitis assessment** using INS Visual Infusion Phlebitis (VIP) Scale: - Grade 0: No symptoms - Grade 1: Slight pain near IV site or slight redness - Grade 2: Pain, redness, and/or swelling at IV site - Grade 3: Pain, redness, swelling, palpable venous cord - Grade 4: Pain, redness, swelling, palpable venous cord > 1 inch, purulent drainage 5. **Infiltration assessment** using INS Infiltration Scale: - Grade 0: No symptoms - Grade 1: Skin blanched, edema < 1 inch, cool to touch, with or without pain - Grade 2: Skin blanched, edema 1–6 inches, cool to touch, with or without pain - Grade 3: Skin blanched/translucent, gross edema > 6 inches, cool to touch, mild-moderate pain, possible decreased pulses - Grade 4: Skin blanched/translucent, tight, leaking, discolored, bruised, swollen, gross edema > 6 inches, deep pitting edema, circulatory impairment, moderate-severe pain; infiltration of blood product, vesicant, or irritant 6. **Patency**: flush easily without resistance; blood return present; no swelling during flush --- ## Step 3 — Maintain IV Site and Infusion System 1. **Dressing changes**: - Transparent semi-permeable dressing: change every 5–7 days (INS standard) or immediately if soiled, loosened, or damp - Gauze dressing: change every 2 days - Apply chlorhexidine-based skin antiseptic; allow to dry completely before applying new dressing 2. **Tubing changes** per INS standards: - Continuous infusions: change primary and secondary sets no more frequently than every 96 hours (unless contaminated or integrity compromised) - Intermittent infusions: change every 24 hours - Blood/blood products: change after each unit or every 4 hours - Lipid-containing solutions (TPN with lipids, propofol): change every 24 hours 3. **Flushing protocol**: - PIV: flush with preservative-free 0.9% sodium chloride before and after each use; minimum 3–5 mL - PICC/CVC: flush with 10 mL preservative-free 0.9% sodium chloride; lock per institutional protocol (heparin or saline) - Use pulsatile flush technique (push-pause) to clear the catheter lumen 4. **Needleless connector**: scrub with 70% isopropyl alcohol for ≥ 5–15 seconds (per institutional policy); allow to dry; change per manufacturer recommendation (typically every 96 hours or every 7 days with compatible IV sets) --- ## Step 4 — Monitor for and Manage IV Complications ### Infiltration/Extravasation - **Stop** the infusion immediately - **Aspirate** residual fluid from the catheter if possible - **Remove** the PIV (do NOT remove if extravasation of a vesicant requiring antidote through the catheter) - **Elevate** the affected extremity - **Apply** warm or cold compresses per drug-specific protocol - **Administer** antidote if vesicant extravasation (e.g., hyaluronidase for vinca alkaloid extravasation, phentolamine for vasopressor extravasation) - **Notify** provider; document per institutional incident reporting ### Phlebitis (VIP Grade ≥ 2) - **Remove** the PIV - **Apply** warm compresses - **Restart** in a different extremity if IV therapy must continue - **Culture** the catheter tip if infectious phlebitis suspected - **Document** VIP grade and interventions ### Catheter-Related Bloodstream Infection (CRBSI) Suspicion - **Obtain** peripheral blood cultures (two sets from two sites) AND culture through the central line (if applicable) BEFORE starting antibiotics - **Notify** provider immediately - **Do not** remove the catheter until provider decision (some CVC infections can be treated with antibiotic lock therapy) - **Document** signs/symptoms, cultures obtained, provider notification ### Air Embolism - **Clamp** the catheter immediately - **Position** patient in left lateral Trendelenburg (Durant's maneuver) - **Administer** 100% oxygen - **Call** rapid response/code - **Document** event details, interventions, patient response --- ## Step 5 — Manage Smart Pump Infusions 1. **Program** the smart pump using the facility-specific drug library — do not use manual/basic mode for medications in the library 2. **Verify** all settings against the order: drug, concentration, dose, rate, volume to be infused 3. **Respond** to all alerts: soft alerts require clinical justification if overridden; hard stops cannot be overridden 4. **Document** any alert overrides with clinical rationale 5. **High-alert infusions** (vasopressors, insulin, heparin, sedation) require independent double-check by second RN 6. **Monitor** infusion site and patient response per drug-specific parameters --- ## Step 6 — Document IV Therapy Management 1. **New insertion**: date, time, inserter, device type, gauge, location, number of attempts, patient tolerance, blood return/flush verification, dressing applied 2. **Shift assessment**: site condition (VIP score, infiltration scale), dressing integrity, securement device status, device necessity review 3. **Maintenance activities**: dressing changes, tubing changes, cap/connector changes with date and time 4. **Infusions**: fluid/medication name, rate, volume, pump settings, patient response 5. **Complications**: description, grade (VIP or infiltration scale), interventions, provider notification, outcome 6. **Removal**: date, time, reason, catheter integrity (tip intact), site condition after removal, hemostasis achieved --- ## Checkpoint B — IV Therapy Review ### Shift-Level Verification - [ ] All IV sites assessed and documented with VIP/infiltration scores - [ ] All dressings inspected for integrity - [ ] Smart pump settings verified against current orders - [ ] Device necessity reviewed: remove PIVs not accessed in 24 hours; daily necessity review for central lines - [ ] Infusion compatibility verified for multi-lumen or piggyback administration - [ ] CLABSI prevention bundle compliance documented for central lines ### Transition-of-Care Verification - [ ] IV access inventory communicated in handoff report - [ ] Infusion status (rate, volume remaining, next bag timing) communicated - [ ] Pending IV medication times communicated - [ ] Anticipated access needs for next shift identified --- ## Quality Audit - [ ] IV site assessment documented per INS frequency standards (q4h PIV, each shift CVC) - [ ] VIP and infiltration scales used for all assessments (not just "site WNL") - [ ] Dressing changes documented within INS timeframes - [ ] PIV dwell time monitored: replace clinically indicated (not routine 72–96h replacement per INS 2021 update) - [ ] CLABSI prevention bundle compliance ≥ 95% for central lines - [ ] Smart pump drug library compliance ≥ 95% - [ ] Infiltration/extravasation events reported through institutional event reporting system - [ ] Compliant with INS Standards of Practice (current edition) - [ ] Compliant with Joint Commission NPSG.07.06.01 for central line management - [ ] Documentation supports defensibility for any IV-related adverse events --- ## Guidelines - **INS Standards of Practice (2021)**: The primary evidence-based reference for all vascular access and infusion therapy nursing practice - **Joint Commission NPSG.07.06.01**: Evidence-based practices for prevention of CLABSI - **CMS**: CLABSI is a Hospital-Acquired Condition; reimbursement implications for hospital-acquired CLABSI - **CDC/HICPAC**: Guidelines for Prevention of Intravascular Catheter-Related Infections (2011, updated) - **NDNQI**: Peripheral IV infiltration rates are a nursing-sensitive quality indicator - **Device dwell time**: INS 2021 recommends clinically indicated removal rather than routine replacement for PIVs; assess for complications rather than replacing on a schedule - **Scope of practice**: RN inserts PIVs, manages infusions, and assesses for complications; PICC insertion may be within RN scope with specialty training per state Nurse Practice Act; CVC insertion is a provider procedure; LPN/LVN IV therapy scope varies by state - **Vesicant extravasation**: Classified as a sentinel event when resulting in significant harm; requires immediate intervention and incident reporting - **Smart pump safety**: Drug library use reduces dosing errors; override rates should be monitored as a safety metric